相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
Ying Yuan et al.
CLINICAL CANCER RESEARCH (2018)
dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials
A. Toumazi et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials
Cody Chiuzan et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2018)
Bayesian optimal interval design for dose finding in drug-combination trials
Ruitao Lin et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2017)
Dose-finding designs for trials of molecularly targeted agents and immunotherapies
Cody Chiuzan et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations
Moreno Ursino et al.
BIOMETRICAL JOURNAL (2017)
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
S. Postel-Vinay et al.
ANNALS OF ONCOLOGY (2016)
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Jeffrey R. Sachs et al.
CLINICAL CANCER RESEARCH (2016)
The changing landscape of phase I trials in oncology
Kit Man Wong et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Seamless Oncology-Drug Development
Tatiana M. Prowell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dose Expansion Cohorts in Phase I Trials
Alexia Iasonos et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov
Stephan Ehrhardt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Early phase clinical trials-are dose expansion cohorts needed?
Alexia Iasonos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A product of independent beta probabilities dose escalation design for dual-agent phase I trials
Adrian P. Mander et al.
STATISTICS IN MEDICINE (2015)
Designs of drug-combination phase I trials in oncology: a systematic review of the literature
M. -K. Riviere et al.
ANNALS OF ONCOLOGY (2015)
A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A plus B designs
Cody Chiuzan et al.
CLINICAL TRIALS (2015)
SEAMLESS PHASE I/II ADAPTIVE DESIGN FOR ONCOLOGY TRIALS OF MOLECULARLY TARGETED AGENTS
Nolan A. Wages et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2015)
Early phase clinical trials to identify optimal dosing and safety
Natalie Cook et al.
MOLECULAR ONCOLOGY (2015)
Adaptive designs for identifying optimal biological dose for molecularly targeted agents
Yong Zang et al.
CLINICAL TRIALS (2014)
Dose-Finding Trial Designs for Combination Therapies in Oncology
Sumithra J. Mandrekar
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Phase I design for completely or partially ordered treatment schedules
Nolan A. Wages et al.
STATISTICS IN MEDICINE (2014)
Phase I/II adaptive design for drug combination oncology trials
Nolan A. Wages et al.
STATISTICS IN MEDICINE (2014)
Design Considerations for Dose-Expansion Cohorts in Phase I Trials
Alexia Iasonos et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
Arif Manji et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adaptive designs for dual-agent phase I dose-escalation studies
Jennifer A. Harrington et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dose-finding design for multi-drug combinations
Nolan A. Wages et al.
CLINICAL TRIALS (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Simultaneously optimizing dose and schedule of a new cytotoxic agent
Thomas M. Braun et al.
CLINICAL TRIALS (2007)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Sequential designs for phase I clinical trials with late-onset toxicities
YK Cheung et al.
BIOMETRICS (2000)
分享论文
